BARD OBTAINS BALLOON-EXPANDABLE CORONARY STENT THROUGH ACQUISITION OF CONTROLLING STAKE IN X-TRODE; FIRM PLANNING PROSTATE CANCER TEST LAUNCHES
This article was originally published in The Gray Sheet
Executive Summary
Bard is gaining its second coronary stent franchise through the purchase of a majority stake in X-Trode, a Bologna, Italy-based company developing a balloon-expandable stainless steel stent.